The Importance of Diversity Within Clinical Trials

The Janssen Pharmaceutical Companies of Johnson & Johnson Diversity, Equity and Inclusion (DE&I) in Clinical Trials team is committed to improving diversity and inclusion in clinical trials to advance health equity and create a better future for all our patients. Janssen created the Research Includes Me program focused on reaching underserved communities by meeting them where they are — on the ground and through addressing barriers to clinical trial participation, leveraging transformative technologies and partnering with trusted community voices.

Factors such as our gender, race, ethnicity, age or lifestyle play an important role in how our bodies respond to different medications or treatments. By including all types of people in our clinical trials, Janssen can determine if new treatments will be safe and work well for as many people as possible, helping to create a better future for all patients.


#TheBalancingAct #balancingact
BSST BACT 0217 720P